Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 170Head & Neck 18Thoracic 15Tumor-Agnostic 8Genitourinary 7Breast 7Other solid neoplasm 6Gynecologic 5CNS 3Sarcoma 2Myeloid 1Endocrine 1

Conditions

Serotonin Syndrome 1Carcinoid Tumor 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panitumumab × Endocrine × Clear all
NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡